Edward Clouston MacPherson - 12 Jun 2026 Form 4 Insider Report for MIRA PHARMACEUTICALS, INC. (MIRA)

Reporting relationship: Director
Issuer ticker: MIRA
Reported as of: 12 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 15 Jun 2026, 17:00:04 UTC
Prior SEC filing: 22 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Edward MacPherson

Key filing fact

Edward Clouston MacPherson filed Form 4 for MIRA PHARMACEUTICALS, INC. (MIRA) on 15 Jun 2026.

Key facts

This page summarizes Edward Clouston MacPherson's Form 4 filing for MIRA PHARMACEUTICALS, INC. (MIRA).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 15 Jun 2026, 17:00.

Change

Previous filing in this sequence was filed on 22 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002015989 Primary reporting owner

MacPherson Edward Clouston

Relationship: Director
Address: C/O MIRA PHARMACEUTICALS, INC., 1200 BRICKELL AVE. SUITE 1950 #1183, MIAMI
Signature: /s/ Edward MacPherson
Signature date: 15 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MIRA transaction Derivative

Stock Options (right to buy)

Award

Transaction value
Shares: +50,000
Change %
Price: $0.000000^*
Shares after: 50,000
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $0.9400
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.

Footnote F2

The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

Footnote F3

Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.